A

Amerisourcebergen Corp
LSE:0HF3

Watchlist Manager
Amerisourcebergen Corp
LSE:0HF3
Watchlist
Price: 249.24 USD -0.59% Market Closed
Market Cap: 51.7B USD
Have any thoughts about
Amerisourcebergen Corp?
Write Note

Amerisourcebergen Corp
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amerisourcebergen Corp
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
Amerisourcebergen Corp
LSE:0HF3
Cost of Revenue
-$284.2B
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
-9%
Cardinal Health Inc
NYSE:CAH
Cost of Revenue
-$216.8B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Henry Schein Inc
NASDAQ:HSIC
Cost of Revenue
-$8.6B
CAGR 3-Years
1%
CAGR 5-Years
-5%
CAGR 10-Years
-2%
Patterson Companies Inc
NASDAQ:PDCO
Cost of Revenue
-$5.2B
CAGR 3-Years
-1%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
Mckesson Corp
NYSE:MCK
Cost of Revenue
-$317.2B
CAGR 3-Years
-10%
CAGR 5-Years
-9%
CAGR 10-Years
-8%
Cencora Inc
NYSE:COR
Cost of Revenue
-$284.2B
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
-9%
No Stocks Found

Amerisourcebergen Corp
Glance View

Market Cap
48.6B USD
Industry
Health Care
Economic Moat
None

AmerisourceBergen Corp. is a leading healthcare services company that plays an essential role in the pharmaceutical supply chain, connecting manufacturers, healthcare providers, and patients. Founded in 2001 and headquartered in Chesterbrook, Pennsylvania, the company has grown through strategic acquisitions and an unwavering commitment to improving patient access to critical medications. AmerisourceBergen stands out by providing a wide range of services, including drug distribution, specialty pharmacy solutions, and healthcare consulting, making it a vital partner for thousands of healthcare organizations across the United States and beyond. By prioritizing innovation and efficiency, they not only streamline pharmaceutical delivery but also enhance patient care in an increasingly complex healthcare landscape. As investors consider AmerisourceBergen, they can take comfort in the company’s impressive financial performance and resilience against market fluctuations. With a robust revenue stream primarily generated from the distribution of pharmaceuticals, AmerisourceBergen benefits from the growing demand for healthcare products and services. Additionally, the company's strategic partnerships and investment in technology position it well for future growth, particularly in the specialty drug sector, which is expanding rapidly due to the rise of biologics and personalized medicine. AmerisourceBergen's focus on operational excellence and customer satisfaction not only fosters loyalty among its clients but also supports a stable and attractive investment outlook, making it a compelling option for those looking to capitalize on the evolving healthcare market.

0HF3 Intrinsic Value
454.17 USD
Undervaluation 45%
Intrinsic Value
Price
A

See Also

What is Amerisourcebergen Corp's Cost of Revenue?
Cost of Revenue
-284.2B USD

Based on the financial report for Sep 30, 2024, Amerisourcebergen Corp's Cost of Revenue amounts to -284.2B USD.

What is Amerisourcebergen Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-9%

Over the last year, the Cost of Revenue growth was -12%. The average annual Cost of Revenue growth rates for Amerisourcebergen Corp have been -11% over the past three years , -10% over the past five years , and -9% over the past ten years .

Back to Top